Clinical Trials
32 trialsAdebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
Sun Yat-sen University
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
FIL_PTCL13
Fondazione Italiana Linfomi - ETS
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Ruijin Hospital
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Sun Yat-sen University
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Peking University Cancer Hospital & Institute
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
Peking Union Medical College Hospital
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
University of Colorado, Denver
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
National Health Research Institutes, Taiwan
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Sun Yat-sen University
THEORY
Ruijin Hospital
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
Peking Union Medical College Hospital
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
PDX+Romi
Columbia University
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Ruijin Hospital
A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Fox Chase Cancer Center
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Peking Union Medical College Hospital
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
Chonnam National University Hospital
RomiCar
University of Birmingham
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
ACCAPELA
Ontario Clinical Oncology Group (OCOG)
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Ro-CHOP
The Lymphoma Academic Research Organisation
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas
Samsung Medical Center